Trial Profile
A Randomised, Double Blind, Placebo Controlled Study to Evaluate the Micro-macroscopic Effects on Muscles, the Safety and Tolerability, and the Efficacy of Givinostat in Patients With Becker Muscular Dystrophy (BMD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jan 2022
Price :
$35
*
At a glance
- Drugs Givinostat (Primary)
- Indications Duchenne muscular dystrophy
- Focus Proof of concept; Therapeutic Use
- Sponsors Italfarmaco
- 12 Jul 2021 Status changed from active, no longer recruiting to completed.
- 26 Jun 2021 Results published in an Italfarmaco media release.
- 26 Jun 2021 Primary endpoint has not been met. (Mean change in mean Cross Sectional Area (CSA)), according to an Italfarmaco media release.